DYAI - Dyadic International, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.62
-0.32 (-5.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close5.94
Open5.88
Bid4.50 x 1000
Ask6.47 x 800
Day's Range5.46 - 5.93
52 Week Range1.77 - 7.30
Volume227,940
Avg. Volume83,915
Market Cap153M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.26
Earnings DateNov 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.33
  • DYAI: Glycosylation Milestone Opens Doors For mAb Production
    Zacks Small Cap Research

    DYAI: Glycosylation Milestone Opens Doors For mAb Production

    By John Vandermosten, CFA NASDAQ::DYAI Dyadic (NASDAQ:DYAI) achieved an impressive milestone in its glycoengineering efforts which was announced via VTT’s 1 presentation at the Protein and Antibody Engineering Summit (PEGS) Europe in Lisbon a few weeks ago. The event was memorialized in a press release on November 25th. It announced that Dyadic’s filamentous fungi expression system Myceliophthora

  • Is Dyadic International, Inc. (DYAI) A Good Stock To Buy?
    Insider Monkey

    Is Dyadic International, Inc. (DYAI) A Good Stock To Buy?

    Before we spend days researching a stock idea we like to take a look at how hedge funds and billionaire investors recently traded that stock. Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018. This means hedge funds […]

  • ACCESSWIRE

    Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line

    JUPITER, FL / ACCESSWIRE / November 25, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, announced that data presented at the annual PEGS Europe Protein & Antibody Engineering Summit demonstrated that its C1 strain has been successfully glyco-engineered to impart the core human like G0 glycan structure at high levels. The G0 glycosylation data was presented by Markku Saloheimo, Ph.D., from the VTT Technical Research Centre of Finland Ltd ("VTT") at the conference in Lisbon, Portugal on Thursday, November 21.

  • DYAI: Third Quarter 2019 Financial & Operational Results
    Zacks Small Cap Research

    DYAI: Third Quarter 2019 Financial & Operational Results

    By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) released third quarter 2019 financial and operational results on November 13, 2019. Revenues were $0.5 million and represented research and development proceeds from partners working to develop C1. Total expenses were $2.4 million and net loss was ($1.7) million after adding interest

  • ACCESSWIRE

    Dyadic Reports Third Quarter 2019 Results And Recent Developments

    New Fully Funded Research Collaboration with Leading Animal Health Company; Fifth Partnership in Animal Sector Expansion of Existing Research Collaboration to Express an Additional Protein with Major Animal ...

  • We Think Dyadic International (NASDAQ:DYAI) Can Easily Afford To Drive Business Growth
    Simply Wall St.

    We Think Dyadic International (NASDAQ:DYAI) Can Easily Afford To Drive Business Growth

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • ACCESSWIRE

    Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019

    JUPITER, FL / ACCESSWIRE / October 30, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended September 30, 2019 after the market close on Wednesday, November 13, 2019 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.

  • ACCESSWIRE

    Dyadic Announces New Collaboration with Leading Animal Health Company

    JUPITER, FL / ACCESSWIRE / October 28, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global platform biotechnology company, announced today that it has entered into a fully funded collaboration with one of the leading animal health companies to demonstrate the C1 technology for expression and production of therapeutic proteins for companion and farm animal health diseases. Under the terms of the agreement, Dyadic will apply its proprietary and patented C1 gene expression platform to express three different types of proteins to be evaluated by our collaborator for its potential use in their research and commercial projects. There is a growing market demand among animal health companies to find a faster and more efficient gene expression technology platform.

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference Lineup for October 15 and 16 - 2019

    AUSTIN, TX / ACCESSWIRE / October 15, 2019 / The MicroCap Rodeo's inaugural event is set for October 15, and 16 th , 2019 in Austin Texas at the Hilton downtown Austin. Focused on the best ideas concept, ...

  • ACCESSWIRE

    Dyadic to Attend Three Upcoming Investor Conferences in October

    JUPITER, FL / ACCESSWIRE / October 10, 2019 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary ...

  • The Dyadic International (NASDAQ:DYAI) Share Price Is Up 327% And Shareholders Are Delighted
    Simply Wall St.

    The Dyadic International (NASDAQ:DYAI) Share Price Is Up 327% And Shareholders Are Delighted

    While Dyadic International, Inc. (NASDAQ:DYAI) shareholders are probably generally happy, the stock hasn't had...

  • ACCESSWIRE

    MicroCap Rodeo Investor Conference - October 15 and 16, 2019, Austin Texas

    Company lineup is filling up fast with 50 good names in the microcap markets, as well as some great private and Pre-IPO companies AUSTIN, TX / ACCESSWIRE / September 19, 2019 / The MicroCap Rodeo's inaugural ...

  • ACCESSWIRE

    Dyadic to Present at Janney Healthcare Conference

    Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins.

  • Zacks Small Cap Research

    DYAI: Another Top Tier Collaboration

    Revenues were $0.4 million and represented research and development proceeds from partners working to develop C1. The second quarter continued the trend of securing collaboration agreements. A 15-year agreement with Serum Institute of India was signed on May 8th to develop twelve proteins.

  • ACCESSWIRE

    Dyadic Reports Second Quarter 2019 Results and Recent Developments

    New Fully Funded Research Collaboration With a Top Tier Pharmaceutical Company Expanded Technology Platform Through Multiple Collaborations and Sublicensing Agreements Robust Scientific Data Reported Up ...

  • Do Insiders Own Shares In Dyadic International, Inc. (NASDAQ:DYAI)?
    Simply Wall St.

    Do Insiders Own Shares In Dyadic International, Inc. (NASDAQ:DYAI)?

    The big shareholder groups in Dyadic International, Inc. (NASDAQ:DYAI) have power over the company. Institutions will...

  • ACCESSWIRE

    Dyadic to Report Second Quarter 2019 Financial Results on Tuesday August 13, 2019

    JUPITER, FL / ACCESSWIRE / July 30, 2019 / Dyadic International, Inc. (“Dyadic”) (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to help accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products at flexible commercial scales, today announced that it will report its financial results for the quarter ended June 30, 2019 after the market close on Tuesday, August 13, 2019 and it will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products.

  • Zacks Small Cap Research

    DYAI: Extension of VTT Contract

    By John Vandermosten, CFA NASDAQ:DYAI Dyadic International Inc. (NASDAQ:DYAI) has continued to maintain its high level of operational intensity since reporting first quarter earnings in early May. The ...

  • ACCESSWIRE

    Dyadic Extends Research and Development Agreement with VTT

    JUPITER, FLORIDA / ACCESSWIRE / July 5, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global platform biotechnology company, announced today that it has extended its research and development contract ("Contract") through June 2022 with VTT Technical Research Centre of Finland Ltd. ("VTT"), a world leading synthetic biology research and development organization. Under the terms of this extended multi-year agreement, Dyadic will provide funding to VTT to continue to apply its advanced synthetic biology methods, including VTT's patented synthetic promoters to further engineer the Company's C1 cell line. Dyadic will provide additional funding to VTT for certain Dyadic internal research projects and other third party collaborations, including Sanofi and the Serum Institute of India.

  • ACCESSWIRE

    Dyadic Joins Russell Microcap(R) Index

    JUPITER, FL / ACCESSWIRE / July 2, 2019 / Dyadic International, Inc. ("Dyadic" or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, announced today that the Company was added to the Russell Microcap® Index effective July 1, as a result of the annual Russell index reconstitution. "Our addition to the Russell Microcap Index is another significant achievement for the Company and reflective of our continued growth," said Mark Emalfarb, Chief Executive Officer. Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes.

  • ACCESSWIRE

    Dyadic Announces Appointment of Ping Rawson to CFO

    JUPITER, FL / ACCESSWIRE / June 27, 2019 / Dyadic International, Inc. ("Dyadic") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs and other biologic products, at flexible commercial scales, today announced the appointment of Ping Rawson to Chief Financial Officer, effective immediately. Ms. Rawson was previously the Chief Accounting Officer of Dyadic and joined the Company in 2016.

  • ACCESSWIRE

    Dyadic to Ring the Nasdaq Closing Bell on June 17, 2019

    JUPITER, FL / ACCESSWIRE / June 11, 2019 / Dyadic International, Inc. ("Dyadic", or the "Company") (DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scale today announced that its President and Chief Executive Officer, Mark Emalfarb, other members of the management team, and other guests will ring the Nasdaq closing bell on Monday, June 17, 2019. The Dyadic closing bell ceremony will be broadcast live on June 17, 2019 starting at 3:45 pm Eastern Time from the Nasdaq MarketSite Studio in Times Square, New York City. You will be able to view the live Nasdaq closing bell ringing ceremony at https://livestream.com/nasdaq/live or http://Facebook.com/Nasdaq.

  • Why Dyadic International, Inc.'s (NASDAQ:DYAI) CEO Pay Matters To You
    Simply Wall St.

    Why Dyadic International, Inc.'s (NASDAQ:DYAI) CEO Pay Matters To You

    Mark Emalfarb has been the CEO of Dyadic International, Inc. (NASDAQ:DYAI) since 2004. First, this article will...

  • Zacks Small Cap Research

    DYAI: Partnerships Accelerate

    Dyadic International Inc. (DYAI) released first quarter 2019 financial and operational results on May 9, 2019.  Revenues were $0.4 million and represented research and development proceeds from partners working to develop C1.  Total expenses were $2.8 million and net loss was ($2.2) million after adding interest income and making a small adjustment for taxes.  Loss per share was ($0.08).  Total cash and investments were $40.0 million at year end, equivalent to ~$1.50 per share. The year started off on with a whirlwind of collaboration announcements.  Two were announced during the first quarter with top 25 pharmaceutical companies and three additional agreements were announced in the last ten days.  These included the Australian Luina Bio, Florida-based Alphazyme and the Serum Institute of India.  Several other positive events occurred since the beginning of the year including the company’s Form 10 being deemed effective by the SEC, uplisting to the NASDAQ, publication of a patent for flu vaccine production and a research project focused on developing adeno-associated viral vectors.